Superluminal Medicines, Inc.
Superluminal Medicines is a biotech company revolutionizing small molecule drug discovery through advanced computational methods, deep biology, and data-driven approaches. They are expanding their team to include talented scientists who build innovative platforms to accelerate and improve the development of medicines.
Superluminal Medicines is a biotechnology company accelerating drug discovery and development to deliver next‑generation small‑molecule therapeutics. Their Hyperloop™ platform combines structure‑based drug design with AI‑driven computational methods and experimental validation to identify and optimize candidates. Initially focused on GPCR targets, their pipeline emphasizes patient‑centric precision to develop treatments for cardiometabolic diseases.
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
Jun 23, 2025
Superluminal joins a $1.3B deal with series A backer Lilly
Aug 14, 2025
Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals
Aug 28, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Superluminal Medicines, Inc..
Superluminal Medicines Closes $120 Million Series A Round
Sep 9, 2024
Senior Director, Head of Structural Biology
Revolution Medicines
Sr. Director/Executive Director, Computational Chemistry
preludetx
Scientist
Corteva Agriscience
Postdoctoral Fellowship
Medical College of Wisconsin
Postdoctoral Researcher – Neurodegenerative diseases
University Health Network
Senior Director, AIRx Computational Chemistry
Takeda Pharmaceutical Company Limited